ATNM Investor Alert: Class Action Lawsuit Filed Against Actinium Pharmaceuticals, Inc.

NEW YORK, March 30, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a recognized law firm specializing in investor representation, has announced the filing of a class action lawsuit against Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") and some of its executives.

Class Action Overview

This lawsuit aims to seek damages for violations of federal securities laws on behalf of all individuals and entities that purchased or acquired Actinium securities from March 31, 2022 to August 2, 2024, which are the dates included in this "Class Period." Those who believe they qualify as investors are encouraged to participate by visiting the firm's dedicated page.

Details of the Case

The Complaint claims that during the Class Period, the Defendants made false and misleading statements that misled investors into thinking that the Food and Drug Administration (FDA) was likely to approve Actinium's Biologics License Application (BLA) for Iomab-B. Specifically, the allegations include that the Defendants consistently highlighted positive data from the Phase 3 Sierra trial while underplaying the significance of the trial's inability to produce statistically significant Overall Survival data. They also allegedly misrepresented the FDA's stance on the trial's design, indicating that the poor Overall Survival data would not impede the BLA's approval.

Next Steps for Investors

A class action lawsuit has already been initiated. Investors who wish to view the Complaint can find it on the firm's website, or they can reach out directly to the firm’s representatives. If you incurred losses related to Actinium, you must act before May 26, 2025, to request being appointed as a lead plaintiff in this lawsuit. Remember, participation in any potential recovery does not require lead plaintiff status.

No Financial Risk

The firm operates on a contingency fee basis, meaning that legal fees will be covered by any recovery obtained, and clients will not have to pay out-of-pocket expenses unless the case is won.

Why Choose Bronstein, Gewirtz & Grossman?

Bronstein, Gewirtz & Grossman, LLC is a leading national firm that has successfully handled securities fraud class actions and shareholder derivative lawsuits. They have a proven track record of recovering significant sums for investors across the country.

Stay Updated

Investors can follow the firm for updates on social media platforms like LinkedIn, Twitter, and Facebook.

Attorney advertising. Previous results do not guarantee the same outcomes in future cases.

Contact Information

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Nathan Miller

Phone: 332-239-2660

Email: [email protected]

lawsuit, investors, Actinium